Potential Roles of EZH2, Bmi-1 and MiR-203 in Cell Proliferation and Invasion in Hepatocellular Carcinoma Cell Line Hep3B

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2015 Dec 31

PMID 26715809

Citations 17

Authors

Fang Yang

Li-Zhi Lv

Qiu-Cheng Cai

Yi Jiang

Affiliations

Soon will be listed here.

Abstract

Aim: To investigate the potential roles of enhancer of zeste homolog2 (EZH2), Bmi-1 and miR-203 in cell proliferation and invasion in hepatocellular carcinoma (HCC) cell line Hep3B.

Methods: A total of 73 patients who underwent surgical resection at Fuzong Clinical Medical College of Fujian Medical University were enrolled in this study. Hep3B cells were cultivated in RPMI 1640 medium supplemented with 10% fetal bovine serum at 37 °C. Vectors that containing cDNA of the EZH2 gene or miR-203 targeted shRNA plasmid were constructed, and then transfected into Hep3B cells. The mRNA expression of miR-203, EZH2, and Bmi-1 was analyzed using quantitative real-time polymerase chain reaction analysis, and the protein levels of EZH2 and Bmi-1 were detected by Western blot analysis. Effect of EZH2 or miR-203 on cell proliferation was observed by methyl thiazolyl tetrazolium assay, and cell apoptosis was assessed using flow cytometry. Besides, effect of EZH2 or miR-203 on tumor cell invasion was detected using Transwell assay.

Results: The mRNA levels of EZH2 and Bmi-1 in HCC tissues and in Hep3B cells were significantly higher compared with those in normal samples (P < 0.01), while miR-203 level was significantly lower in HCC tissues (P < 0.01). Hep3B cells transfected with EZH2-shRNA or miR-203-shRNA showed lower expression levels of EZH2 and Bmi-1 (P < 0.05). Compared with controls, Hep3B cells transfected with EZH2-shRNA had relative slow cell proliferation, indicating that low expression of EZH2 and Bmi-1 and overexpression of miR-203 could inhibit Hep3B cell proliferation (P < 0.05). The average apoptosis rate of Hep3B cells transfected with EZH2-shRNA vector was about 18.631%, while that of Hep3B cells transfected with shRNA vector was about 5.33%, suggesting that EZH2 was down-regulated by transfecting with EZH2-shRNA, and the down-regulated EZH2 contributed to the cell apoptosis. Low expression of EZH2 and Bmi-1 and overexpression of miR-203 could reduce Hep3B cell invasion (P < 0.05).

Conclusion: Our study suggests that EZH2 and Bmi-1 are up-regulated while miR-203 is down-regulated in Hep3B cells. MiR-203 may contribute to the metastasis and enhance apoptosis of HCC cells by regulating EZH2 and Bmi-1. Our study may provide a theoretical basis for metastasis of HCC and targeted therapy of HCC.

Citing Articles

MicroRNA-Mediated Regulation of Histone-Modifying Enzymes in Cancer: Mechanisms and Therapeutic Implications.

Szczepanek J, Tretyn A Biomolecules. 2023; 13(11).

PMID: 38002272 PMC: 10669115. DOI: 10.3390/biom13111590.

Predicting the prognosis of hepatocellular carcinoma based on the interaction between pyroptosis, apoptosis, and necroptosis.

Qian F, Kong W, Wang S, Wei K Clin Exp Med. 2022; 23(6):2087-2104.

PMID: 36271962 DOI: 10.1007/s10238-022-00910-4.

The Crucial Roles of Bmi-1 in Cancer: Implications in Pathogenesis, Metastasis, Drug Resistance, and Targeted Therapies.

Xu J, Li L, Shi P, Cui H, Yang L Int J Mol Sci. 2022; 23(15).

PMID: 35897796 PMC: 9367737. DOI: 10.3390/ijms23158231.

Roles of BMI1 in the Initiation, Progression, and Treatment of Hepatocellular Carcinoma.

Wang R, Fan H, Sun M, Lv Z, Yi W Technol Cancer Res Treat. 2022; 21:15330338211070689.

PMID: 35072573 PMC: 8793120. DOI: 10.1177/15330338211070689.

The Epigenetic Modulation of Cancer and Immune Pathways in Hepatitis B Virus-Associated Hepatocellular Carcinoma: The Influence of HBx and miRNA Dysregulation.

Sartorius K, An P, Winkler C, Chuturgoon A, Li X, Makarova J Front Immunol. 2021; 12:661204.

PMID: 33995383 PMC: 8117219. DOI: 10.3389/fimmu.2021.661204.

References

Jin J, Deng J, Wang F, Xia X, Qiu T, Lu W . The expression and function of microRNA-203 in lung cancer. Tumour Biol. 2012; 34(1):349-57. DOI: 10.1007/s13277-012-0556-3. View

Wei W, Wanjun L, Hui S, Dongyue C, Xinjun Y, Jisheng Z . miR-203 inhibits proliferation of HCC cells by targeting survivin. Cell Biochem Funct. 2012; 31(1):82-5. DOI: 10.1002/cbf.2863. View

Li X, Yang Z, Song W, Zhou L, Li Q, Tao K . Overexpression of Bmi-1 contributes to the invasion and metastasis of hepatocellular carcinoma by increasing the expression of matrix metalloproteinase (MMP)‑2, MMP-9 and vascular endothelial growth factor via the PTEN/PI3K/Akt pathway. Int J Oncol. 2013; 43(3):793-802. DOI: 10.3892/ijo.2013.1992. View

Karakatsanis A, Papaconstantinou I, Gazouli M, Lyberopoulou A, Polymeneas G, Voros D . Expression of microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance. Mol Carcinog. 2012; 52(4):297-303. DOI: 10.1002/mc.21864. View

Cheng Y, Chen T, Fan H, Yu C, Chang H, Hsieh C . Transarterial chemoembolization for intrahepatic multiple recurrent HCC after liver resection or transplantation. Ann Transplant. 2014; 19:309-16. DOI: 10.12659/AOT.890505. View

Ciarapica R, De Salvo M, Carcarino E, Bracaglia G, Adesso L, Leoncini P . The Polycomb group (PcG) protein EZH2 supports the survival of PAX3-FOXO1 alveolar rhabdomyosarcoma by repressing FBXO32 (Atrogin1/MAFbx). Oncogene. 2013; 33(32):4173-84. DOI: 10.1038/onc.2013.471. View

Fu W, Tang L, Zhu X, Lu Y, Zhang Y, Lee W . MiR-218-targeting-Bmi-1 mediates the suppressive effect of 1,6,7-trihydroxyxanthone on liver cancer cells. Apoptosis. 2014; 20(1):75-82. DOI: 10.1007/s10495-014-1047-3. View

Tung-Ping Poon R, Fan S, Wong J . Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg. 2000; 232(1):10-24. PMC: 1421103. DOI: 10.1097/00000658-200007000-00003. View

Raaphorst F, van Kemenade F, Blokzijl T, Fieret E, Hamer K, Satijn D . Coexpression of BMI-1 and EZH2 polycomb group genes in Reed-Sternberg cells of Hodgkin's disease. Am J Pathol. 2000; 157(3):709-15. PMC: 1885707. DOI: 10.1016/S0002-9440(10)64583-X. View

10.

Furuyama T, Tie F, Harte P . Polycomb group proteins ESC and E(Z) are present in multiple distinct complexes that undergo dynamic changes during development. Genesis. 2003; 35(2):114-24. DOI: 10.1002/gene.10173. View

11.

Lessard J, Sauvageau G . Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature. 2003; 423(6937):255-60. DOI: 10.1038/nature01572. View

12.

Gong Y, Wang X, Liu J, Shi L, Yin B, Peng X . NSPc1, a mainly nuclear localized protein of novel PcG family members, has a transcription repression activity related to its PKC phosphorylation site at S183. FEBS Lett. 2004; 579(1):115-21. DOI: 10.1016/j.febslet.2004.11.056. View

13.

Breuer R, Snijders P, Smit E, Sutedja T, Sewalt R, Otte A . Increased expression of the EZH2 polycomb group gene in BMI-1-positive neoplastic cells during bronchial carcinogenesis. Neoplasia. 2005; 6(6):736-43. PMC: 1531677. DOI: 10.1593/neo.04160. View

14.

Thomas M, Zhu A . Hepatocellular carcinoma: the need for progress. J Clin Oncol. 2005; 23(13):2892-9. DOI: 10.1200/JCO.2005.03.196. View

15.

Sudo T, Utsunomiya T, Mimori K, Nagahara H, Ogawa K, Inoue H . Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma. Br J Cancer. 2005; 92(9):1754-8. PMC: 2362028. DOI: 10.1038/sj.bjc.6602531. View

16.

Liu S, Dontu G, Mantle I, Patel S, Ahn N, Jackson K . Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res. 2006; 66(12):6063-71. PMC: 4386278. DOI: 10.1158/0008-5472.CAN-06-0054. View

17.

Mihic-Probst D, Kuster A, Kilgus S, Bode-Lesniewska B, Ingold-Heppner B, Leung C . Consistent expression of the stem cell renewal factor BMI-1 in primary and metastatic melanoma. Int J Cancer. 2007; 121(8):1764-70. DOI: 10.1002/ijc.22891. View

18.

Wang H, Pan K, Zhang H, Weng D, Zhou J, Li J . Increased polycomb-group oncogene Bmi-1 expression correlates with poor prognosis in hepatocellular carcinoma. J Cancer Res Clin Oncol. 2007; 134(5):535-41. DOI: 10.1007/s00432-007-0316-8. View

19.

Ladeiro Y, Couchy G, Balabaud C, Bioulac-Sage P, Pelletier L, Rebouissou S . MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology. 2008; 47(6):1955-63. DOI: 10.1002/hep.22256. View

20.

Sasaki M, Ikeda H, Itatsu K, Yamaguchi J, Sawada S, Minato H . The overexpression of polycomb group proteins Bmi1 and EZH2 is associated with the progression and aggressive biological behavior of hepatocellular carcinoma. Lab Invest. 2008; 88(8):873-82. DOI: 10.1038/labinvest.2008.52. View